---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-25-000008"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2025-02-20T23:59:59+00:00"
generated_at: "2026-05-26T08:28:52.738146+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Travere Q4 FILSPARI sales $49.6M; plans FSGS sNDA by end Q1 2025

## Summary
- Q4 total net product sales $73.5M (FILSPARI $49.6M); FY total $226.7M (FILSPARI $132.2M).
- Plans to submit sNDA for FILSPARI in FSGS around end of Q1 2025, based on Phase 3 DUPLEX and Phase 2 DUET.
- FDA granted full approval for IgAN in Sept 2024; received 693 new patient start forms in Q4.
- Pegtibatinase Phase 3 HARMONY restart expected in 2026 after manufacturing scale-up improvements.
- Cash and marketable securities $370.7M as of Dec 31, 2024, including $134.7M from Nov stock offering.

## SEC filing metadata
- accession: 0001438533-25-000008
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2025-02-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853325000008/0001438533-25-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853325000008/tvtx-20250220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-25-000008
- JSON: https://secwatch.observer/filing/0001438533-25-000008.json
- Plain text: https://secwatch.observer/filing/0001438533-25-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.